ClinicalTrials.gg
RecruitingNCT06535568PIV-EPICUpdated Jan 22, 2026

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

An interventional study of Drug-coated balloon and Single antiplatelet therapy (SAPT) in Coronary Disease, Heart Diseases and Cardiovascular Diseases, sponsored by Fondazione Ricerca e Innovazione Cardiovascolare ETS. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Fondazione Ricerca e Innovazione Cardiovascolare ETS · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
576
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Coronary Disease with a site in Italy — 10 open to participants now, 13 under way, none of them phase 3. Coronary Disease · Italy.

Planned enrollment
18th of 37
576 · median 476
Started
2026
the only one that year
No phase
17 of 58
4 open now
Primary completion
2028-01
later than 11 of 12 live
Registered
55th of 58
by date

Among the 58 studies in Coronary Disease with a site in Italy, this one is the 18th largest by planned enrollment of the 37 interventional ones that give a count, is the only one that started in 2026, is one of 17 with no phase, reaches primary completion later than 11 of the 12 other live ones, and was the 55th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

10 of the 58 studies in Coronary Disease with a site in Italy are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Coronary Disease with a site in Italy, or all of them as a file.
02

Study summary

This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients undergoing percutaneous coronary intervention (PCI) with the latest generation drug-coated balloon (DCB). The study includes patients with stable or unstable coronary syndromes and aims to assess rates of ischemic and bleeding adverse events.

Read the detailed description

The purpose of the PICCOLETO IV-EPIC 38 study is to observe and evaluate the efficacy and safety of single antiplatelet therapy (SAPT) after successful PCI with the Essential Pro drug-coated balloon in native coronary artery disease in vessels with a diameter between 2.0 and 4.0 mm, compared to routine dual antiplatelet therapy (DAPT). Patients aged 75 years or older, or those at high bleeding risk, with stable or unstable coronary syndromes will be enrolled and randomized in this study.

03

Conditions studied

  • Coronary Disease
  • Heart Diseases
  • Cardiovascular Diseases
  • Myocardial Ischemia
  • Atherosclerosis
  • Arterial Occlusive Diseases
  • Vascular Diseases
  • Coronary Artery Disease
  • Acute Coronary Syndrome
  • Coronary Stenosis
  • Molecular Mechanisms of Pharmacological Action
  • Enzyme Inhibitors
  • MTOR Inhibitors
  • Protein Kinase Inhibitors
  • Physiological Effects of Drugs
  • Immunosuppressive Agents
  • Antineoplastic Agents
  • High Bleeding Risk
  • Single Antiplatelet Therapy
  • Dual Antiplatelet Therapy
  • Cyclooxygenase Inhibitors
  • P2Y12 Inhibitor
  • Platelet Aggregation Inhibitors
  • Aspirin
  • Clopidogrel

Keywords

  • DCB
  • Angioplasty
  • Paclitaxel
  • Antiplatelet treatment
  • Single antiplatelet therapy (SAPT)
  • Dual antiplatelet therapy (DAPT)
  • High bleeding risk (HBR)
  • MACE
  • Native CAD
  • stable or unstable coronary syndromes
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male and female patients who meet the following criteria:

  • Age ≥ 75 years or age ≥ 18 years at high bleeding risk;
  • Successful PCI with Essential Pro DCB just performed, in 1, 2 or 3 coronary vessels;
  • Stable or unstable coronary syndromes;
  • De novo coronary lesions in vessels with diameter ≥2.0 and ≤4.0 mm (visual estimation);
  • to participate in the study given by the patient or impartial witness.

Exclusion criteria

Exclusion Criteria:

  • Stent implantation during index or recent (\<6 months) procedure;
  • Known (and untreatable) or to aspirin, heparin, clopidogrel, paclitaxel or contrast media, or any of their which cannot be adequately pre-medicated;
  • Pregnancy at the time of hospitalization;
  • Patients participating in another clinical study in which an drug or device was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer;
  • ST-elevation myocardial infarction;
  • \<12 months;
  • \<30%;
  • Visible thrombus at lesion site;
  • Target lesion/vessel with any of the following characteristics:

    • severe and/or >270° calcification of the target vessel, also proximal to the lesion (intravascular imaging not mandatory);
    • left main stem stenosis >50%;
    • target lesion is in the left main stem;
    • chronic total occlusion with anticipated necessity of retrograde approach;
    • lesion is in a bypass graft.
  • History of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory medicines (NSAIDs);
  • History of gastrointestinal perforation, ulceration, or bleeding (peptic ulcer bleeding-PUBs) related to previous use of NSAIDs or anticoagulant medications, or intracranial hemorrhage;
  • Acute gastrointestinal ulcers;
  • Hemorrhagic diathesis (including known bleeding disorders or ongoing active bleeding);
  • Severe renal impairment ( \< 30 mL/min);
  • Severe hepatic impairment ( C), with elevated liver enzymes (/AST > 2 x or total >1.5 x ULN);
  • Severe cardiac failure ( grade III or IV);
  • Combination with methotrexate at doses of 15 mg/week or more;
  • Patients with baseline \< 1500 cells/mm³;
  • Breastfeeding women;
  • Full-blown thyrotoxicosis;
  • Patients with a very high risk of thrombosis.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
576 participants (estimated)

Study arms

  • Experimental
    Single antiplatelet therapy

    Device: Drug-coated balloon · Drug: Single antiplatelet therapy (SAPT)

  • Active comparator
    Dual antiplatelet therapy

    Device: Drug-coated balloon · Drug: Dual antiplatelet therapy (DAPT)

Interventions

  • DeviceDrug-coated balloon

    Essential Pro paclitaxel eluting coronary balloon dilatation catheter is a rapid exchange catheter, also known as RX because it has a proximal simple lumen configuration and a distal coaxial dual lumen, intended for coronary arteries percutaneous transluminal angioplasties. Patients assigned to this Arm will be treated with a Drug-Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care.

  • DrugSingle antiplatelet therapy (SAPT)

    The antithrombotic regimen is single antiplatelet therapy (SAPT). The Investigator will decide if to use aspirin or clopidogrel, whereas ticagrelor or prasugrel are not recommended in our study population since no benefit (or even harm) has been shown by these drugs in head-to-head trials versus clopidogrel in elderly PCI populations. The type of agent and treatment duration will be selected according to the clinical characteristics of the patient.

  • DrugDiaminohydroxypropanetetraacetic acidStudies of Diaminohydroxypropanetetraacetic acidDiaminohydroxypropanetetraacetic acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The antithrombotic regimen will follow the standard of care with a dual antiplatelet regimen (DAPT) per local preferences and international guidelines/ARC consensus paper. The type of agent and treatment duration will be selected according to the patient's clinical characteristics.

06

What researchers measure

Primary outcomes

  1. Rate of Net Adverse Clinical Events (NACE) at 12 months

    Superiority of single antiplatelet therapy (SAPT) versus dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients undergoing percutaneous coronary intervention (PCI) with drug-coated balloons (DCB), assessed by the rate of Net Adverse Clinical Events (NACE). NACE is defined as the composite of major adverse cardiovascular events (MACE) plus clinically relevant bleeding events classified as BARC 2, 3, or 5, evaluated at 12 months following successful PCI with DCB.

    Time frame: 12 months

Secondary outcomes

  1. Rate of Clinically Relevant Bleeding Events (Bleeding Academic Research Consortium [BARC] Scale, Grades 2-5; range 0-5, where higher grades indicate more severe bleeding and worse clinical outcome)

    Incidence of clinically relevant bleeding events classified as BARC grades 2, 3, or 5 according to the Bleeding Academic Research Consortium (BARC) bleeding definition (scale range 0-5; higher scores indicate worse outcome) in elderly or high bleeding risk patients treated with single antiplatelet therapy (SAPT) versus dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) with drug-coated balloon (DCB).

    Time frame: 12 months

  2. Procedural success rate immediately post-PCI

    Defined as final stenosis \<30%, distal TIMI 3 flow, and no major in-hospital adverse events.

    Time frame: Post-PCI

  3. Patient-oriented composite endpoint (PoCE)

    Composite of all-cause death, all myocardial infarctions (MIs), or any repeat revascularization.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • IRCCS Auxologico Milano
    Milan, MI 20149, Italy
    Recruiting
    • Davide Dr Sala · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2028, 24 months after the start.

Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 24 months is close to that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Aug 2, 2024
StartActual
Jan 10, 2026
Primary completionEst.
Jan 20, 2028
CompletionEst.
Feb 20, 2028
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06535568
Lead sponsor
Fondazione Ricerca e Innovazione Cardiovascolare ETS
Collaborators
Fundación EPIC
Responsible party
Sponsor
First posted
Aug 2, 2024
Start date
Jan 10, 2026
Primary completion
Jan 20, 2028 (estimated)
Completion
Feb 20, 2028 (estimated)
Last update
Jan 22, 2026

Study contacts

Bernardo Cortese, MD MSc
Contact
bcortese@gmail.com
216-296-9747
Beatrice Barbano
Contact
segreteria@fondazioneric.org

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion